In this issue:
Bimekizumab over 2 years for moderate-to-severe plaque psoriasis
Guselkumab for psoriasis with an inadequate response to ustekinumab
MPO loss-of-function associated with generalised pustular psoriasis
Economic burden of palmoplantar pustulosis
Long-term HRQoL with certolizumab pegol in plaque psoriasis
Characterising risk factors for psoriasis hospitalisation
Dimethyl fumarate for moderate-to-severe plaque psoriasis
Fumaric acid esters for plaque-type psoriasis
Trends in prescriptions of oral medications for psoriasis
Please login below to download this issue (PDF)